Cargando…

Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?

Background and Objectives: Long-acting somatostatin analogues (SSA) (octreotide LAR and lanreotide Autogel) are recommended as first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Sowa-Staszczak, Anna, Opalińska, Marta, Kurzyńska, Anna, Morawiec-Sławek, Karolina, Gilis-Januszewska, Aleksandra, Palen-Tytko, Joanna, Olearska, Helena, Hubalewska-Dydejczyk, Alicja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708475/
https://www.ncbi.nlm.nih.gov/pubmed/34946232
http://dx.doi.org/10.3390/medicina57121287
_version_ 1784622694168264704
author Sowa-Staszczak, Anna
Opalińska, Marta
Kurzyńska, Anna
Morawiec-Sławek, Karolina
Gilis-Januszewska, Aleksandra
Palen-Tytko, Joanna
Olearska, Helena
Hubalewska-Dydejczyk, Alicja
author_facet Sowa-Staszczak, Anna
Opalińska, Marta
Kurzyńska, Anna
Morawiec-Sławek, Karolina
Gilis-Januszewska, Aleksandra
Palen-Tytko, Joanna
Olearska, Helena
Hubalewska-Dydejczyk, Alicja
author_sort Sowa-Staszczak, Anna
collection PubMed
description Background and Objectives: Long-acting somatostatin analogues (SSA) (octreotide LAR and lanreotide Autogel) are recommended as first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of these SSAs are usually administered via injections repeated every 4 weeks. The purpose of the study was to compare the route of SSA administration (injection performed by professional medical staff and self-administration of the drug) with progression-free survival. Materials and methods: 88 patients in 2019 and 96 patients in 2020 with locally advanced or metastatic well-differentiated NETs were included in the study. All patients had a good expression of SSTR type 2 and had been treated for at least 3 months with a stable dose of long-acting somatostatin analogue every 4 weeks. All of them had received training on drug self-injections from professional NET nurses at the beginning of the COVID-19 epidemic. Results: The rate of NET progression in the study group in 2020 was higher than in 2019 29.1% vs. 18.1% (28 vs. 16 cases), p = 0.081. Conclusions: The method of administration of long-acting SSA injection performed by professional medical staff vs. self-injection of the drug may significantly affect the risk of NET progression. The unequivocal confirmation of such a relationship requires further observation.
format Online
Article
Text
id pubmed-8708475
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87084752021-12-25 Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome? Sowa-Staszczak, Anna Opalińska, Marta Kurzyńska, Anna Morawiec-Sławek, Karolina Gilis-Januszewska, Aleksandra Palen-Tytko, Joanna Olearska, Helena Hubalewska-Dydejczyk, Alicja Medicina (Kaunas) Article Background and Objectives: Long-acting somatostatin analogues (SSA) (octreotide LAR and lanreotide Autogel) are recommended as first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of these SSAs are usually administered via injections repeated every 4 weeks. The purpose of the study was to compare the route of SSA administration (injection performed by professional medical staff and self-administration of the drug) with progression-free survival. Materials and methods: 88 patients in 2019 and 96 patients in 2020 with locally advanced or metastatic well-differentiated NETs were included in the study. All patients had a good expression of SSTR type 2 and had been treated for at least 3 months with a stable dose of long-acting somatostatin analogue every 4 weeks. All of them had received training on drug self-injections from professional NET nurses at the beginning of the COVID-19 epidemic. Results: The rate of NET progression in the study group in 2020 was higher than in 2019 29.1% vs. 18.1% (28 vs. 16 cases), p = 0.081. Conclusions: The method of administration of long-acting SSA injection performed by professional medical staff vs. self-injection of the drug may significantly affect the risk of NET progression. The unequivocal confirmation of such a relationship requires further observation. MDPI 2021-11-23 /pmc/articles/PMC8708475/ /pubmed/34946232 http://dx.doi.org/10.3390/medicina57121287 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sowa-Staszczak, Anna
Opalińska, Marta
Kurzyńska, Anna
Morawiec-Sławek, Karolina
Gilis-Januszewska, Aleksandra
Palen-Tytko, Joanna
Olearska, Helena
Hubalewska-Dydejczyk, Alicja
Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
title Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
title_full Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
title_fullStr Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
title_full_unstemmed Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
title_short Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
title_sort self-administration of long-acting somatostatin analogues in net patients—does it affect the clinical outcome?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708475/
https://www.ncbi.nlm.nih.gov/pubmed/34946232
http://dx.doi.org/10.3390/medicina57121287
work_keys_str_mv AT sowastaszczakanna selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome
AT opalinskamarta selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome
AT kurzynskaanna selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome
AT morawiecsławekkarolina selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome
AT gilisjanuszewskaaleksandra selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome
AT palentytkojoanna selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome
AT olearskahelena selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome
AT hubalewskadydejczykalicja selfadministrationoflongactingsomatostatinanaloguesinnetpatientsdoesitaffecttheclinicaloutcome